The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Four children born with a rare genetic form of severe blindness have all experienced significant improvements in their ...